tiprankstipranks
Purple Biotech’s NT219 Shows Promising Cancer Fight
Company Announcements

Purple Biotech’s NT219 Shows Promising Cancer Fight

Purple Biotech Ltd. (PPBT) has released an update.

Pick the best stocks and maximize your portfolio:

Purple Biotech Ltd. has announced exciting developments for its cancer drug NT219, revealing its potential to suppress cancer stem cells and resist tumor recurrence at the upcoming AACR 2024 conference. The drug, which is in a clinical trial phase, has also shown promise in identifying biomarkers for treatment success. Purple Biotech’s continuous progress in oncology drug development marks a significant stride in the fight against solid-tumor cancers.

For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPurple Biotech Advances Oncology Drugs with New Funding
TipRanks Auto-Generated NewsdeskPurple Biotech Secures $2.8 Million for Oncology Advancements
TipRanks Auto-Generated NewsdeskPurple Biotech Signs Securities Purchase Agreement
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App